Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2236435 | 1.00 | — | — | |
| SCHEMBL755867 | 0.89 | — | — | |
| SCHEMBL5665559 | 0.86 | — | — | |
| SCHEMBL19218138 | 0.84 | TSHR (0.36) | KDM4E | |
| SCHEMBL1169615 | 0.84 | — | — | |
| SCHEMBL3225586 | 0.84 | — | — | |
| SCHEMBL3462646 | 0.84 | — | — | |
| SCHEMBL20073871 | 0.83 | KDM4E (0.31) | L3MBTL1POLBKDM4ELMNATP53 | |
| SCHEMBL974736 | 0.83 | — | — | |
| SCHEMBL1865122 | 0.83 | SLC6A4 (0.30) | GAASLC6A4SLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306816-B1 | Use of topical compositions for the preservation of a human or animal body | ARKEMA FRANCE (FR) | 2015-04-08 | — | — | EP | claimed |
| US-20110104097-A1 | TOPICAL COMPOSITIONS FOR THE PRESERVATION OF A HUMAN OR ANIMAL BODY | ARKEMA FRANCE (FR) | 2011-05-05 | — | — | US | claimed |
| EP-1938684-B1 | Use of polyoxymethylendialkylethers and/or dialdehydacetals for the preservation of human or animal bodies and compositions comprising the same | ARKEMA FRANCE (FR) | 2009-07-22 | — | — | EP | claimed |
| US-20080166315-A1 | Use of Compounds for the Preservation of the Human or Animal Body and Compositions Comprising Same | ARKEMA FRANCE | 2008-07-10 | — | — | US | claimed |
| EP-1938684-A1 | Use of compounds of formula (I) and/or (II) for the preservation of human or animal bodies and compositions comprising the same | ARKEMA FRANCE (FR) | 2008-07-02 | — | — | EP | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-11820725-B2 | Process for catalytic hydrogenation of halonitroaromatics | MONSANTO TECHNOLOGY LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11549020-B2 | Curable composition for nano-fabrication | CANON KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| US-11549020-B2 | Curable composition for nano-fabrication | CANON KABUSHIKI KAISHA (JP) | 2023-01-10 | — | — | US | disclosed |
| EP-3356033-B1 | PROCESS FOR CATALYTIC HYDROGENATION OF HALONITROAROMATICS | MONSANTO TECHNOLOGY LLC (US) | 2022-10-19 | — | — | EP | disclosed |
| US-20220098141-A1 | PROCESS FOR CATALYTIC HYDROGENATION OF HALONITROAROMATICS | MONSANTO TECHNOLOGY LLC (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3202757-B1 | METHOD FOR PRODUCING A POLYETHER DIOL | MITSUBISHI GAS CHEMICAL CO (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-6288181-B1 | CATALYSIS WITH TRANSITION METAL METALLOCENE COMPOUND AND ETHER; REDUCING ELECTROSTATIC CHARGE | EASTMAN CHEMICAL COMPANY | 2001-09-11 | — | — | US | disclosed |
| US-6271321-B1 | CATALYTIC POLYMERIZATION OR COPOLYMERIZATION OF ETHYLENE AND OLEFIN MONOMERS | EASTMAN CHEMICAL COMPANY | 2001-08-07 | — | — | US | disclosed |
| WO-2000058373-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000058372-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000058371-A1 | PROCESS FOR PRODUCING POLYOLEFINS | EASTMAN CHEMICAL COMPANY (US) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000052069-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000052068-A1 | PROCESS FOR PRODUCING POLYETHYLENE | EASTMAN CHEMICAL COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166315-A1 | Use of Compounds for the Preservation of the Human or Animal Body and Compositions Comprising Same | ALKBH2, ALDH2, ENO1 | L3MBTL1 2401/4885GAA 1990/4885POLB 862/4885 |
| US-11820725-B2 | Process for catalytic hydrogenation of halonitroaromatics | HDHD5, HPD, HAO2 | L3MBTL1 3529/4885GAA 2314/4885POLB 543/4885 |
| US-20110104097-A1 | TOPICAL COMPOSITIONS FOR THE PRESERVATION OF A HUMAN OR ANIMAL BODY | FUCA1, PIGS, UNG | L3MBTL1 2237/4885GAA 43/4885POLB 1074/4885 |
| US-20220098141-A1 | PROCESS FOR CATALYTIC HYDROGENATION OF HALONITROAROMATICS | HDHD5, HPD, HAO2 | L3MBTL1 3529/4885GAA 2314/4885POLB 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.